Andrea Alimonti, MD
![Andrea Alimonti, MD](https://res.cloudinary.com/pcf/images/w_300,h_300,c_scale/fl_lossy/f_auto,q_auto/v1565722287/Andrea_Alimonti_512x512_jaiei5/Andrea_Alimonti_512x512_jaiei5.jpg?_i=AA)
About Andrea Alimonti, MD
Dr. Alimonti’s research is focused on the characterization of a novel type of cellular senescence response which is elicited by complete loss of the tumor suppressor PTEN, and on the identification of novel compounds with pro-senescence activity. The final aim is to develop the concept of pro-senescence therapy for cancer, from experimental evidences to clinic, investigating the efficacy of “pro-senescence” compounds in phase I clinical trials. This will also allow for the identification of senescence markers in human tumor samples to be used in clinic.
Designation: Group Leader
University:
Institute of Oncology Research